Circulating Micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection

Department of Obstetrics and Gynaecology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
PLoS ONE (Impact Factor: 3.53). 01/2012; 7(1):e29770. DOI: 10.1371/journal.pone.0029770
Source: PubMed

ABSTRACT MicroRNAs (miRNAs, miRs) are a class of small, non-coding RNA molecules with relevance as regulators of gene expression thereby affecting crucial processes in cancer development. MiRNAs offer great potential as biomarkers for cancer detection due to their remarkable stability in blood and their characteristic expression in many different diseases. We investigated whether microarray-based miRNA profiling on whole blood could discriminate between early stage breast cancer patients and healthy controls.
We performed microarray-based miRNA profiling on whole blood of 48 early stage breast cancer patients at diagnosis along with 57 healthy individuals as controls. This was followed by a real-time semi-quantitative Polymerase Chain Reaction (RT-qPCR) validation in a separate cohort of 24 early stage breast cancer patients from a breast cancer screening unit and 24 age matched controls using two differentially expressed miRNAs (miR-202, miR-718).
Using the significance level of p<0.05, we found that 59 miRNAs were differentially expressed in whole blood of early stage breast cancer patients compared to healthy controls. 13 significantly up-regulated miRNAs and 46 significantly down-regulated miRNAs in our microarray panel of 1100 miRNAs and miRNA star sequences could be detected. A set of 240 miRNAs that was evaluated by radial basis function kernel support vector machines and 10-fold cross validation yielded a specificity of 78.8%, and a sensitivity of 92.5%, as well as an accuracy of 85.6%. Two miRNAs were validated by RT-qPCR in an independent cohort. The relative fold changes of the RT-qPCR validation were in line with the microarray data for both miRNAs, and statistically significant differences in miRNA-expression were found for miR-202.
MiRNA profiling in whole blood has potential as a novel method for early stage breast cancer detection, but there are still challenges that need to be addressed to establish these new biomarkers in clinical use.

Download full-text


Available from: Michael G Schrauder, Aug 10, 2015
1 Follower
  • Source
    • "To date , only one study has evaluated the levels of circulating miR - 202 in the blood of breast cancer patients . This study showed that miR - 202 was significantly upregulated in whole blood samples of early - stage breast cancer patients performing microarray and quantitative PCR ( Schrauder et al , 2012 ) . "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background:MAGE-A (melanoma-associated antigen-A) are promising targets for specific immunotherapy and their expression may be induced by the epigenetic factor BORIS.Methods:To determine their relevance for breast cancer, we quantified the levels of MAGE-A1, -A2, -A3, -A12 and BORIS mRNA, as well as microRNAs let-7b and miR-202 in pre- and postoperative serum of 102 and 34 breast cancer patients, respectively, and in serum of 26 patients with benign breast diseases and 37 healthy women by real-time PCR. The mean follow-up time of the cancer patients was 6.2 years.Results:The serum levels of MAGE-A and BORIS mRNA, as well as let-7b were significantly higher in patients with invasive carcinomas than in patients with benign breast diseases or healthy women (P<0.001), whereas the levels of miR-202 were elevated in both patient cohorts (P<0.001). In uni- and multivariate analyses, high levels of miR-202 significantly correlated with poor overall survival (P=0.0001). Transfection of breast cancer cells with synthetic microRNAs and their inhibitors showed that let-7b and miR-202 did not affect the protein expression of MAGE-A1.Conclusions:Based on their cancer-specific increase in breast cancer patients, circulating MAGE-A and BORIS mRNAs may be further explored for early detection of breast cancer and monitoring of MAGE-directed immunotherapies. Moreover, serum miR-202 is associated with prognosis.British Journal of Cancer advance online publication, 1 July 2014; doi:10.1038/bjc.2014.360
    British Journal of Cancer 07/2014; DOI:10.1038/bjc.2014.360 · 4.82 Impact Factor
  • Source
    • "The procedure of qRT-PCR followed previous studies (Schrauder et al., 2012). Briefly, total RNA was isolated from the dissected cord homogenate using Trizol, and complimentary DNA was generated from 1 lg total RNA using a PrimerScript RT reagent kit with gDNA Eraser. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The immediate-early gene, c-jun, is expressed in spinal motoneurons after spinal root avulsion. The expression of c-jun was suggested to be necessary for motoneuron survival and regeneration after avulsion. In the present study, a short interfering RNA (siRNA) was delivered intrathecally to the injured spinal segments immediately after root avulsion in rats to knock down expression of the c-jun gene in injured spinal motoneurons so as to explore the role of c-jun in the motoneurons in vivo. Our results showed that the siRNA not only inhibited the expression of both c-jun mRNA and protein but also augmented the death of injured motoneurons at day 14 post-injury. These findings indicated that induction of c-jun gene expression plays a pivotal role in the survival of injured motoneurons. Meanwhile, these results suggest that siRNAs applied intrathecally can effectively mediate expression of the c-jun gene in injured motoneurons.
    Neuroscience 03/2013; 241. DOI:10.1016/j.neuroscience.2013.03.006 · 3.33 Impact Factor
  • Source
    • "Several studies have demonstrated miRNAs in human serum or plasma are very stable (Chen et al., 2008; Mitchell et al., 2008; McDonald et al., 2011). Specific circulating miRNAs were found to be potential diagnostic, prognostic, or metastatic markers with very high validity (sensitivity and specificity) (Huang et al., 2010; Brase et al., 2011; Zheng et al., 2011; Zhou et al., 2011; Liu et al., 2012; Schrauder et al., 2012). Recently, seven miRNAs (miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a, and miR-801) in plasma were combined as a diagnostic panel, which was found to be a better diagnostic marker to distinguish HCC and healthy controls (Zhou et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: microRNAs (miRNAs) are small non-coding RNAs that regulate gene expression through post-transcriptional interactions with mRNA. miRNAs have recently emerged as key regulators of various cancers. Although miR- 27a has been implicated in several other cancers, its role in hepatitis B virus-related hepatocellular carcinoma (HCC) is unknown. In this study, we showed miR-27a to be frequently up-regulated in HCC tissues and HCC cell lines (HepG2 and Huh7). Overexpression of miR-27a enhanced cell proliferation, promoted migration and invasion, and activated cell cycling in HepG2 and Huh7 cells. In summary, our results suggest that up-regulation of miR-27a may play an oncogenic role in the development of HCC and might thus be a new therapeutic target in HCC patients.
    Asian Pacific journal of cancer prevention: APJCP 02/2013; 14(2):885-9. DOI:10.7314/APJCP.2013.14.2.885 · 2.51 Impact Factor
Show more